Chen Fu is an Oncology physician. OpenAlex indexes 115 publications with 2,416 citations (h-index 24); ClinicalTrials.gov lists 11 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
550 1st Ave
New York, NY 100166402
Telephone
212-263-5506Provider last certified this registry record 8 Sept 2024.
Clinical trials
- Automated Trainer-Based Gait Rehabilitation for Hemiplegic Stroke Patients
Sponsor: Cheng-Hsin General Hospital
- Gait Training for Hemiplegic Stroke Patients With Stationary Trainer
Sponsor: Cheng-Hsin General Hospital
- An Investigation of the Gait Performance and Balance in Yoga Instructors
Sponsor: Cheng-Hsin General Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year20252 payments
- AstraZeneca Pharmaceuticals LPProgram year20241 payment
- Daiichi Sankyo Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
32.9%Corticosteroid19.4%Prednisone100%Part D≥17 patientsSerotonin-3 Receptor Antagonist13.5%Ondansetron Hcl100%Part D≥17 patientsNervous system
19.4%Opioid Agonist12.9%Oxycodone Hcl50%Tramadol Hcl50%Part D<11 patientsPhenothiazine6.5%Prochlorperazine Maleate100%Part D<11 patientsCancer & immunology
17.6%Kinase inhibitor17.6%Tafinlar63%Mekinist37%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The future of pharmaceuticals: Artificial intelligence in drug discovery and development
Journal of Pharmaceutical Analysis
2025 - Discovery of polypyridyl iridium(III) complexes as potent agents against resistant Candida albicans
European Journal of Medicinal Chemistry
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”